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Abstract
Background
Risk stratification of hospital patients for adverse drug events would enable targeting
patients who may benefit from interventions aimed at reducing drug-related morbidity. It
would support clinicians and hospital pharmacists in selecting patients to deliver a more effi-
cient health care service. This study aimed to develop a prediction model that helps to iden-
tify patients on the day of hospital admission who are at increased risk of developing a
clinically relevant, preventable adverse drug event during their stay on a surgical ward.
Methods
Data of the pre-intervention measurement period of the P-REVIEW study were used. This
study was designed to assess the impact of a multifaceted educational intervention on clini-
cally relevant, preventable adverse drug events in surgical patients. Thirty-nine variables
were evaluated in a univariate and multivariate logistic regression analysis, respectively.
Model performance was expressed in the Area Under the Receiver Operating Characteris-
tics. Bootstrapping was used for model validation.
Results
6780 admissions of patients at surgical wards were included during the pre-intervention period
of the PREVIEW trial. 102 patients experienced a clinically relevant, adverse drug event during
their hospital stay. The prediction model comprised five variables: age, number of biochemical
tests ordered, heparin/LMWH in therapeutic dose, use of opioids, and use of cardiovascular
drugs. The AUROC was 0.86 (95% CI 0.83–0.88). The model had a sensitivity of 80.4% and a
specificity of 73.4%. The positive and negative predictive values were 4.5% and 99.6%,
respectively. Bootstrapping generated parameters in the same boundaries.
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Conclusions
The combined use of a limited set of easily ascertainable patient characteristics can help
physicians and pharmacists to identify, at the time of admission, surgical patients who are at
increased risk of developing ADEs during their hospital stay. This may serve as a basis for
taking extra precautions to ensure medication safety in those patients.
Introduction
Pharmacotherapy is one of the most commonly applied interventions in hospital healthcare.
In addition to the beneficial effects, prescribing medication also introduces risks of medication
errors and adverse drug events that can lead to potentially preventable morbidity, mortality,
and costs [1–3]. Patients on surgical wards are particularly at risk, due to their need for pain
medication and antibiotics, frequent adjustments of antithrombotic regimens, and blood and
fluid loss. In the case of elderly surgical patients, multiple co-morbidities requiring multiple
drugs contribute even more to potential drug-related problems [4].
Risk prediction is a routine component in daily care practice in both specific areas (e.g.
approaches used to determine stroke risk in patients with atrial fibrillation) as well as more
generally, for example in identifying patients likely to require hospital admission. Risk stratifi-
cation of hospital patients for adverse drug events (ADE) can target a population that can ben-
efit from interventions aimed to reduce drug-related morbidity, as a form of personalized
medicine. It can support clinicians and hospital pharmacists in patient prioritization to deliver
more efficient health care service [5]. In a systematic review Yourman et al. emphasized that
failure to consider risk prediction in a clinical setting can result in poor patient outcomes [6].
A recent review identified four studies that developed and validated ADE risk-prediction
tools for use in adults over 65 years of age [4, 5, 7–9]. These prediction models had poor to
modest performance and did not address clinical impact, thereby limiting clinical usefulness.
Because a large number of variables contribute to ADE occurrence in patients, it is impossible
to precisely predict every ADE in every patient. Therefore, Stevenson et al. suggested that these
risk prediction strategies should focus either on one specific harmful ADE (e.g. gastrointestinal
or intracranial bleeding) or ADEs in patients with a particular illness or clinical characteristic,
for instance surgical patients [5]. In addition, since the aim is to prevent patient harm, it seems
more rational to predict clinically relevant, potentially preventable adverse events, instead of
adverse reactions in general.
The P-REVIEW study (Pharmacist-led Risk patients medication EValuation to Initiate Event
reduction on surgical Wards) was designed to determine whether a multifaceted intervention
comprised of educating the prescriber combined with medication review and pharmaceutical
visits to the ward by the hospital pharmacist could lead to a reduction of adverse drug events
among surgical patients [10]. In this study, experts assessed clinically relevant, potentially pre-
ventable ADE in a cohort of 13,264 admissions of surgical patients. An ADE was classified as
clinically relevant when it was fatal, life-threatening, disabling, incapacitating, or when it resulted
in or prolonged hospitalisation. When an ADE resulted from suboptimal care, it was classified as
potentially preventable. The study showed a significant benefit for patients in the intervention
period. To improve the cost effectiveness of medication review and other measures to prevent
avoidable harm, it would be useful to identify patients at risk of clinically relevant ADEs in the
surgical ward. For this purpose, we used the P-REVIEW data to develop a risk-prediction model
that could identify patients at risk of a clinically relevant, potentially preventable adverse drug
event during admission to the surgical ward, on the day of hospital admission.
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Materials and methods
Study setting and population
The P-REVIEW study is a prospective open intervention study designed to investigate whether
a multifaceted educational intervention could lead to a reduction of clinically relevant, poten-
tially preventable adverse drug events among patients in surgical wards. The study was per-
formed in two large general teaching hospitals in the Netherlands and has been described in
detail elsewhere [10]. Patients who were admitted to the surgical, urological, or orthopaedic
ward of one of the two hospitals during a period of six months were included. In case of read-
mission, patients could be included more than once. Day care patients were excluded. For the
development of the prediction model, data were used from patients during the pre-interven-
tion period.
P-REVIEW data set
Data available in the P-REVIEW dataset were collected for each admission, including patient
characteristics, drug history, and biochemical, haematological, and microbiological markers.
The major part of the data collection was performed automatically from the EHR (Electronic
Health Record). In addition, some of the data were collected manually by a review of medical
records.
Data from the day of admission of each patient was extracted. If more laboratory values
were available of the same variable, the last one, being the most recent value available, was
extracted.
Assessment of clinically relevant, potentially preventable adverse drug events that led to
death, temporary or permanent disability, increased length of hospital stay, or readmission
within 30 days was performed in the P-REVIEW study by teams of experts consisting of a hos-
pital pharmacist and a hospital-based physician, who were not affiliated with the study hospitals.
To classify seriousness the National Coordinating Council for Medication Error Reporting and
Prevention (NCC MERP) index was used. Categories E to I of this index were considered to be
clinically relevant. The causality between prescription error and the drug related problem was
assessed using the algorithm by Kramer et al. The potential preventability was assessed using
the algorithm according to Schumock et al., modified by Lau et al. [10].
Predicting variables
From the data that were collected in the P-REVIEW study, candidate model parameters were
selected on the basis of reports in the literature of their association with ADEs [1–4, 11–18].
Thirty-nine risk factors were identified, including patient characteristics (age, gender), department
of admission (general surgery versus orthopaedic surgery and urology), type of admission (emer-
gency versus elective); medication (number of medications, use of gastrointestinal drugs, hypogly-
cemic drugs, vitamin K antagonists, heparin or low molecular weight heparin (LMWH) in
therapeutic dose, thrombocyte aggregation inhibitors, cardiovascular drugs in general, cardiac
drugs, diuretics, betablockers, renin angiotensin system (RAS) inhibitors, antilipaemica, cortico-
steroids, antimicrobials, chemotherapy, non-steroidal anti-inflammatory drugs (NSAIDs), opioids,
antiepileptics, central nervous system (CNS) agents in general, antipsychotics, anxiolytics, antide-
pressants, and serious drug-drug interactions); laboratory test results (albumin, glucose, hemoglo-
bin, international normalized ratio (INR), potassium, sodium, leucocytes, chronic kidney disease
epidemiology (CKD-EPI), oxygen saturation, positive microbiological blood culture, number of
biochemical tests ordered (<20 versus20)) [1–4, 11–18]. Drugs were coded according to the
Anatomical Therapeutic and Chemical codes [19]. The glomerular filtration rate was computed
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by the Chronic Kidney Disease Epidemiology Collaboration formula (CKD-EPI)[20]. Missing
data where imputed using the ‘multiple imputation’ procedure from SPSS version 22. SPSS uses a
Markov Chain Monte Carlo (MCMC) algorithm known as Fully Conditional Specification (FCS).
This method can be used when the pattern of missing data is arbitrary. For each iteration and for
each variable in the order specified in the variable list, the FCS method fits a univariate (single
dependent variable) model using all other available variables in the model as predictors. Linear
regression was used to predict a scale variable and logistic regression to predict categorical vari-
ables. Variables of which more than 60% of data were missing were left out of the analysis.
Model development
Model development consisted of two stages [21]. In the first stage, possible predictors were
tested using a univariate binary logistic regression model. Variables that were found to be sta-
tistically significant (P<0.05) were taken forward to the next stage of multivariate analysis.
In case of variables that in clinical practice can be either too high or too low and confer risk
in both situations, categorization of variables was performed (for instance, low potassium
values< 3.5 mmol/l, normal values between 3.5 and 5.0 mmol/l and high values> 5.0 mmol/l).
In the second stage, backward and forward elimination procedures were used in multivari-
ate logistic regression analysis in order to detect the best predictors. The removal criterion was
set at p = 0.10.
Results from the univariate and multivariate logistic regression models were expressed in
terms of the odds ratio with 95% confidence intervals and p-values.
Standardized odd ratios were computed to allow for comparison of the strength of the asso-
ciation between the various continuous variables and the probability of an ADE. Standardiza-
tion was achieved through Z-transformation.
Model performance
Model performance of the logistic regression model was expressed in the Area Under the
Curve (AUC) as computed by a Receiver Operating Characteristics curve analysis (ROC analy-
sis) using the probability as predicted by the regression model and the real outcome (ADE).
Model validation
Bootstrapping was used to assess the internal validity of the model. Two hundred bootstrap
samples were drawn to assess the reliability of the model expressed in over-optimism and the
uniform shrinkage factor.
Statistical analyses were performed using SPSS Statistics version 22 (IBM Software, New
York). Bootstrapping was performed in SAS version 9.4.
Ethics
For all stages of this research, patient records were anonymized prior to analysis in accordance
with prevailing privacy regulations.
The institutional review boards of the Isala Hospital and the Meander Medical Center in
the Netherlands stated that the study was exempt from ethical approval.
Results
The pre-intervention period of the P-REVIEW dataset study population comprised 6780
admissions of 5940 patients at surgical wards. A clinically relevant, potentially preventable
adverse drug event during hospital stay, which led to death, temporary or permanent disability,
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increased length of hospital stay or readmission within 30 days was determined in 102 patients.
The most frequent types of events were haemorrhage (19), arterial or venous thrombosis(7),
renal insufficiency, dehydration or electrolyte related events (13), drug intoxication in renal
insufficiency (4), central nervous system events (48) and faecal impaction (11). Characteristics
of patients who did, and those who did not experience an ADE during hospital stay are shown
in Table 1.
Univariate analysis
The candidate predictive variables of a clinically relevant ADE during hospital stay and results
of the univariate analysis are reported in Table 2.
Multivariate analysis
The significant variables (p<0.05) were identified from the univariate analysis and taken for-
ward to the next stage.
In all 20 imputed datasets, both backward and forward elimination procedure in multivari-
ate analysis identified the same 5 variables that were significantly associated with the risk of
developing a clinically relevant adverse drug event. It appeared that these 5 predictor variables
did not have missing values. Therefore, the final analysis could be performed with the original,
complete dataset.
The coefficients (ß), standard errors (SE), and odds ratios (OR) with 95% confidence inter-
vals of the variables are shown in Table 3. The final model comprised age, number of biochem-
ical tests ordered, heparin/LMWH in therapeutic dose, use of opioids, and use of
cardiovascular drugs at the time of hospital admission.
The AUC of the model was 0.858 (95% CI 0.831–0.884). The ROC curve is shown in Fig 1.
The validation of the model using bootstrap samples showed an over-optimism of 0.008 and a
shrinkage factor of 0.960, leading to a corrected performance of the model of 0.85 (Table 3).
When the cut-off point for a high risk of developing an ADE was set at 1.6%, the model
showed a sensitivity of 80.4% and a specificity of 73.4%. At this cut-off level, positive and nega-
tive predictive value were 4.5% and 99.6%, respectively.
The formula of the logistic regression model that allows for calculating the individual risk
of a clinically relevant adverse drug event to a surgical patient is shown below.
Formula individual risk = 1/(1 + exp(-1LP))
Table 1. Patient characteristics.
Admissions with a clinically relevant
ADE(n = 102)
Admissions without a clinically relevant
ADE(n = 6678)
Mean age of patients in
years ± SD
78.7 ± 8.7 63.1 ± 17.6
Gender of patients, n (%)
female
50(49.0%) 3331 (49.9%)
Department of admission,
n (%)
General surgery 67 (65.7%) 3824 (57.3%)
Urology 4 (3.9%) 1244 (18.6%)
Orthopedic surgery 31 (30.4%) 1610 (24.1%)
Admission, n (%) elective 39 (38.2%) 4194 (62.8%)
No. of medications
(mean ± SD)
11.1 ± 4.8 6.6 ± 5.5
https://doi.org/10.1371/journal.pone.0201645.t001
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Table 2. Candidate predictive variables.
Univariate analysis Standardized OR
Predictive variables(references) N missing (%) OR CI P-value
Patient characteristics
Age (years) 0 (0) 1.09 1.07–1.09 <0.0001 4.33 (3.11–6.03)
Gender (m/f) 0 (0) 0.97 0.65–1.43 0.862
Department of admission 204 (3.1) 0.004
General Surgery vs Urology 4.95 1.79–13.65 0.002
Orthopedic S vs Urology 5.89 2.07–16.28 0.001
Admission (emergency vs elective) 235 (3.5) 2.91 1.94–4.37 <0.0001
Medication use (ATC-code)
No. of medications 0 (0) 1.13 1.10–1.16 <0.0001 1.94 (1.65–2.29)
Serious drug-drug interactionsb 0 (0) 3.99 2.20–7.24 <0.0001
Gastrointestinal drugs (A02) 0 (0) 1.60 1.08–2.37 0.019
Hypoglycemics (A10) 0 (0) 3.17 2.04–4.93 <0.0001
Vitamin K antagonists (B01AA) 0 (0) 2.03 1.04–3.90 0.038
Heparin/LMWH in therapeutic dose (B01AB) 0 (0) 4.23 2.37–7.55 <0.0001
Thrombocyte aggregation inhibitors (B01AC) 0 (0) 3.21 2.14–4.82 <0.0001
Cardiovascular drugs (C) 0 (0) 9.31 5.29–16.38 <0.0001
Cardiac drugs (C01) 0 (0) 3.55 2.23–5.65 <0.0001
Diuretics (C03) 0 (0) 3.70 2.50–5.49 <0.0001
Betablockers (C07) 0 (0) 3.35 2.26–4.76 <0.0001
RAS inhibitors (C09) 0 (0) 3.15 2.12–4.66 <0.0001
Antilipaemicae (C10) 0 (0) 2.36 1.58–3.55 <0.0001
Corticosteroids (H02) 0 (0) 2.01 0.92–4.38 0.078
Antimicrobials (J01,J02) 0 (0) 1.73 1.17–2.56 0.006
Chemotherapy (L01) 0 (0) NA
NSAIDs (M01A) 0 (0) 0.71 0.45–1.13 0.149
Opioids (N02A) 0 (0) 4.39 2.90–6.65 <0.0001
Antiepileptics (N03) 0 (0) 1.59 0.69–3.67 0.273
CNS agents (N05/N06) 0 (0) 4.91 2.70–8.94 <0.0001
Antipsychotics (N05A) 0 (0) 1.65 1.10–2.48 0.015
Anxiolytics (N05B) 0 (0) 1.59 0.84–2.99 0.153
Antidepressants (N06A) 0 (0) 1.71 0.93–3.14 0.086
Laboratory data
Albumin (g/L) 5839 (86.1) 0.96 0.92–1.00 0.055 0.74(0.54–1.01)
Glucose (mmol/L) 5097 (75.2) 1.14 1.04–1.24 0.004 1.40(1.11–1.77)
Hemoglobin (mmol/L)(low vs normal and high)a 3901 (57.5) 2.83 1.48–5.43 0.002
INR (ratio) 5775 (85.2) 1.07 0.84–1.36 0.582 1.08(0.83–1.39)
Potassium (mmol/L) 3085 (45.5) 0.640
(low vs. normal) 0.95 0.43–2.07 0.888
(high vs. normal)a 1.74 0.54–5.65 0.355
Sodium (mmol/L) 3184 (47.0) 0.046
(low vs. normal) 2.06 1.17–3.65 0.013
(high vs. normal)a 1.11 0.15–8.21 0.916
Leucocytes (109/L) 3784 (55.8) 0.98 0.92–1.04 0.475 0.91(0.69–1.19)
CKD-EPI (ml/min/1.73 m2) 3062 (45.1) 0.001
(severely impaired vs. normal) 2.70 1.26–5.80 0.010
(moderately impaired vs. normal))a 2.25 1.40–3.64 0.001
(Continued)
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Where LP is the so called Linear Predictor which for our model is defined as:
Linear Predictor = 10.082 +
0.060  age (in years) +
0.770 (in case number of biochemical tests ordered 20) +
0.604  heparin/LMWH (in therapeutic dose) +
1.261 (in case the patient uses cardiovascular drugs) +
0.785 (in case the patient uses opioids)
Discussion
The risk prediction model resulting from this study helps to identify surgical patients that are
at increased risk of sustaining a clinically relevant potentially preventable adverse drug event.
This model uses five clinical variables that can be obtained routinely on hospital admission,
and that can be incorporated into clinical practice as a tool to target patients that can benefit
from interventions aimed at reducing potentially preventable clinically relevant adverse drug
events during hospital stay in surgical wards.
The model was developed using data from the pre-intervention phase of the P-REVIEW
study, which assessed clinically relevant, potentially preventable ADE among patients at surgi-
cal wards [10]. This is the first study that developed a risk prediction model focusing on
Table 2. (Continued)
Univariate analysis Standardized OR
Predictive variables(references) N missing (%) OR CI P-value
Oxygen saturation (%) 6322 (93.2) NA
Positive microbiological blood culture 0 (0) NA
Number of biochemical tests (20 versus <20) 0 (0) 3.63 2.45–5.37 <0.0001 1.36(1.24–1.48)
Abbreviations: OR, Odds Ratio; CI, confidence interval; GS, general surgery; OS, orthopedic surgery; U, urology; LMWH, low molecular weight heparin; CNS, central
nervous system; INR, international normalized ratio; NA, not applicable/computable;
a. Values for normal ranges were defined as follows: hemoglobin normal values: male 8,5–11,0 mmol/l, female 7,5–10,0 mmol/l; potassium normal values: 3.5–5.0
mmol/l; sodium normal values: 135–145 mmol/l; CKD-EPI: normal values >60, moderately impaired renal failure 30–60, severely impaired renal failure <30 ml/min/
1.73 m2.
b. Serious drug-drug interactions were defined as having the potential to cause long-lived residual symptoms or handicap, failure of life-saving therapy or death. These
interactions were identified using the Dutch national database known as ‘G-Standard’.
https://doi.org/10.1371/journal.pone.0201645.t002
Table 3. Coefficients, standard errors and Odds Ratios (OR) with 95% confidence intervals (CI) of the five variables of the final model. The OR as found after
applying the shrinkage factor is also given.
Logistic regression
ß SE OR (95% CI) OR after applying the shrinkage factor
Age 0.060 .10 1.062 (1.039–1.083) 1.059
Number of biochemical tests.
(20 tests versus <20 tests)
0.770 .208 2.159 (1.181–2.841) 2.094
Heparin/LMWH in therapeutic dose (Y/N) 0.604 .307 1.830 (1.786–3.819) 1.786
Cardiovascular drugs
(Y/N)
1.261 .220 3.529 (1.786–5.902) 3.355
Opioids (Y/N) 0.785 .300 2.192 (1.272–3.278) 2.125
Abbreviations: ß, coefficient; CI, confidence interval; LMWH, low molecular weight heparin; OR,Odds Ratio; SE, standard error;
https://doi.org/10.1371/journal.pone.0201645.t003
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clinically relevant potentially preventable ADE instead of adverse drug reactions in general.
This study only targeted surgical patients, which leads to a better model performance. We only
included variables that are available on the first day after hospital admission to be able to oper-
ationalize a model to predict risk during hospital stay, immediately after hospital admission.
Therefore, variables such as length of hospital stay, interdisciplinary consultation or admission
to the intensive care unit during hospital stay, were not included in our analysis.
Our final model contains five variables; age of the patient, number of biochemical tests
ordered, treatment with heparin/LMWH in therapeutic dose, treatment with opioids, and
treatment with cardiovascular drugs. Our model shows an acceptable level of fit and discrimi-
nation performance. We can use the model not only to label patients at risk of experiencing a
drug-related event but also to label patients that are very unlikely to experience an event. The
negative predictive value of our model is very high. Therefore, one could use this model to also
identify patients for whom automated computerized clinical decision support without surveil-
lance by the hospital pharmacist is sufficient.
An overview of studies of development and validation of risk prediction models for ADR or
ADE is shown in Table 4. Other studies showed different predictive variables and found an
area under the receiver operator characteristic curve (AUROC), varying between 0.70–0.74,
with relatively low sensitivity and specificity scores. We hypothesized that focusing on patient
cohorts with restricted clinical characteristics (surgical patients) and focusing on clinically rel-
evant, potentially preventable adverse drug events, instead of adverse drug reactions in general,
would lead to a better performing prediction model.
In our study, the strongest independent risk factor was the age of the patients. As shown in
many other studies, advancing age is associated with an increased number of comorbidities in
association with polypharmacy resulting in an increased risk of ADEs [2, 3, 13].
This is the first study that explores the number of biochemical tests ordered as a predictive
factor for drug related events. We hypothesized that besides the use of specific laboratory values
as electronic triggers, the number of biochemical tests might also be useful in identifying a risk
of ADE during hospital admission. Before diagnosing the patient’s condition, the physician
may suspect a possible adverse outcome. This suspicion alerts the physician and leads to
Fig 1. The ROC curve of the model.
https://doi.org/10.1371/journal.pone.0201645.g001
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increased laboratory orders to clarify the patient’s condition and to prevent serious problems.
Moreover, deviant laboratory values will lead to further monitoring [22]. Consequently, the
number of biochemical tests might be a useful electronic trigger to identify a patient at risk of
ADE, pointing out an acute unstable clinical situation [16, 23]. In our study this factor has
proven to be a strong predictor for drug related problems in surgical wards.
Surgery in patients who use anticoagulation therapy, is a challenge. Guidelines on periopera-
tive management of anticoagulation are complicated and people are at risk of either bleeding or
thrombosis as a result of the surgical procedures. For patients with a high risk of thromboembo-
lism, measured with a CHA2DS2-VASC score, needing certain surgical procedures, it is neces-
sary to perform bridging with LMWH at therapeutic dose during the perioperative period. If
this procedure is not correctly performed, these patients are at high risk of serious ADEs. Pardo
Carbello et al. already demonstrated that the most frequent fatal ADE is haemorrhage [24].
We found that use of cardiovascular drugs and opioids are significant risk factors in surgical
patients. Cardiovascular drugs are generally used by a vulnerable older population with multiple
co-morbidities. Use of opioids often indicates (temporary) severe morbidity. The literature has
shown that patients using these drugs have an increased risk of experiencing ADEs [15, 25].
Table 4. Overview studies of development and validation of risk prediction models for ADR or ADE.
Study (year) Setting and country Sample size and
population
Outcome Predicting variables in the
model
Model
performance
Model
validation
McElnay et al.
(1997)(7)
General hospital, United
Kingdom
929 patients(> 65
years old)
ADE Digoxine
Antidepressiants
Gastrointestinal disorders
Chronic obstructive airways
disease
Angina
Abnormal potassium level
Thinks drugs are responsible
for hospital admission
AUROC: not
presented
204 patients
Sensitivity 41%
Specificity 69%
Trivalle et al.
(2011)(9)
Geriatric rehabilitation
centers, France
526 patients ADE Number of medications
Antipsychotic treatment
Recent anticoagulant use
AUROC: 0.70 Bootstrapping
Tangiisuran et al.
(2014)(8)
Teaching hospital, United
Kingdom
690 patients (>85
years old)
ADR Hyperlipidemia
Number of medications > 8
Length of stay > 12 days
Antidiabetic drugs
Elevated white cell count
AUROC: 0.74
Sensitivity 80%
Specificity 55%
483 patients
AUROC:0.73
Sensitivity 84%
Specificity 43%
Onder et al.
(2010)(4)
Community and
university-based hospitals,
Italy
5936 elderly patients ADR Number of medications
History of ADR
Heart failure
Liver disease
Presence of 4 or more co-
morbidities
Renal failure
AUROC: 0.71
Sensitivity: 68%
Specificity: 65%
483 patients
AUROC: 0.70
The present study Teaching hospitals, the
Netherlands
6780 admissions of
5940 surgical patients
Clinically relevant,
potentially preventable
ADE
Age
Number of biochemical tests
ordered
Heparin/LMWH in
therapeutic dose
Cardiovascular drugs
Opioids
AUROC: 0.86
Sensitivity: 80%
Specificity: 73%
Bootstrapping
AUROC: 0.85
Abbreviations: ADE: adverse drug event; ADR: adverse drug reaction; AUROC: Area under the Receiver Operator Characteristic Curve; LMWH: low molecular weight
heparin.
https://doi.org/10.1371/journal.pone.0201645.t004
Prediction of clinically relevant adverse drug events in surgical patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0201645 August 23, 2018 9 / 12
This study has several strengths. The P-REVIEW database contains information on clini-
cally relevant potentially preventable drug related events (leading to death, temporary or per-
manent disability, increased hospital stay or readmission) in a very large cohort. Aiming at
prevention of patient harm, it seems more rational to focus on clinically relevant, potentially
preventable adverse events, instead of adverse reactions in general. We focused on patients in
surgical wards. By studying patient cohorts with restricted clinical characteristics the perfor-
mance of risk prediction models will improve. Furthermore, we used variables that can be rou-
tinely obtained on hospital admission, so implementation can easily be operationalized.
There are some limitations to our study. In our analysis, we used potentially predictive vari-
ables that were available in the P-REVIEW database. Mostly, these data were automatically
obtained from hospital databases [10]. The lack of automated coded information for some var-
iables limited the use of these variables, e.g. information on co-morbidities using the Interna-
tional Classification of Diseases (ICD-10), frailty or cognitive impairment, reason for hospital
admission or type of surgery performed. We internally validated our model by bootstrapping
but we have not yet been able to externally validate this model in clinical practice. Because
patients could be included more than once, in case of readmission, this may have led to an
immortal time bias. However, since only a small patients were admitted several times in the
study, we think this bias was very limited.
The development of our risk prediction model has potentially important implications for
clinical practice and research. By using this model, lower-risk patients could be managed less
extensively (for instance, only automatically using CPOE/CDSS), whereas higher risk patients
could receive more intensive interventions, such as medication review, aimed at reducing
drug-related adverse outcomes. Such selective use of ancillary precautions could also help to
improve the cost-effectiveness of medication safety interventions. In that way, this risk model,
which combines clinical and medication related variables can guide clinical intervention,
delivered as part of an integrated system built on the principles of medication safety [5]. Future
research should confirm whether intensive pharmacovigilance of high risk patients really leads
to less adverse drug events in hospitalized patients. Our risk model can be incorporated into a
CPOE system and thereby generate automatic risk-evaluation based on patients’ medical rec-
ords upon hospital admission. Above a pre-specified cut-off point, the score can assist hospital
pharmacists or prescribing physicians in their decisions to review the patient’s medication or
to perform other relevant interventions. Under the cut-off point (not necessarily the same cut-
off point), it may be possible for the hospital pharmacist to prioritize efforts in medication
safety interventions and rely, when possible, on an automatic medication safety system.
Conclusions
A risk prediction model was developed to identify surgical patients at risk of experiencing a
clinically relevant, potentially preventable adverse drug event during hospital admission. The
resulting model contains five variables: age of the patient, number of biochemical tests
ordered, treatment with heparin/LMWH in therapeutic dose, treatment with opioids, and
treatment with cardiovascular drugs. This model can be used to guide the hospital pharmacist
and the physician to effectively and efficiently implement clinical interventions to improve
medication safety.
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